Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders

Mazin, Pavel; Sheshunov, I. V.; Mazina, N. K.

doi:10.17116/jnevro20171173128-39

Cited by 21 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Представленные в базе данных РИНЦ публикации, посвященные результатам клинического применения препарата Цитофлавин® при различных патологических состояниях, могут быть объединены в несколько групп исходя из нозологического принципа. Так, применению препарата при сосудистых заболеваниях нервной системы посвящено несколько исследовательских работ [40,[61][62][63][64][65][66][67][68].…”

Section: анализ результатов клинического применения цитофлавина® при ...unclassified

Pathogenetic and pharmacodynamic features of succinic acid derivative application for various diseases of the cardiovascular and nervous systems

Kim,

Shustov,

Ganapolsky

2024

Psychopharmacology & biological narcology

View full text Add to dashboard Cite

This study revealed the pathogenetic patterns of the development of hypoxic and ischemic disorders in various pathological conditions and substantiated approaches to the use of drugs with antihypoxic activity. The role of the receptor interaction of succinic acid in the composition of succinate-containing antihypoxants with succinate receptor SUCNR1 has been demonstrated. The pharmacodynamic properties of the combined preparation of succinic acid that also contains vitamin precursors of the cofactors of Krebs cycle dehydrogenases nicotinamide (precursor of NAD) and riboflavin mononucleotide (precursor of FAD) and precursor of purine nucleotides (inosine) (cytoflavin) for intravenous drip and oral administration were analyzed. Literature data were also analyzed to evaluate the effectiveness of the use of the metabolic corrector of energy-dependent and hypoxic conditions (cytoflavin) in various central nervous system and cardiovascular diseases. In the case of ischemic disorders of cerebral and coronary blood flow, the effects of the drug are concentrated on the penumbra zone (ischemic penumbra), which is associated with the intravenous administration of the drug to its metabolic activity by influencing endothelial cells, restoring microcirculation, and enhancing the oxygen transport function of the blood. Among the new areas of drug use, the use of cytoflavin in the complex therapy of traumatic brain injuries, traumatic shock, acute respiratory distress syndrome, toxic lesions of the central nervous system, multiple organ failure syndrome, and post-COVID syndrome is promising.

show abstract

Section: анализ результатов клинического применения цитофлавина® при ...unclassified

Pathogenetic and pharmacodynamic features of succinic acid derivative application for various diseases of the cardiovascular and nervous systems

Kim,

Shustov,

Ganapolsky

2024

Psychopharmacology & biological narcology

View full text Add to dashboard Cite

show abstract

Selection of Neuroprotective Therapy in Patients with Chronic Cerebral Ischemia Taking Account of the Synergism of Drug Interactions

Громова

Torshin

Путилина

et al. 2021

Neurosci Behav Physi

View full text Add to dashboard Cite

Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)

Харитонова¹,

Shvarts

Verbovoy³

et al. 2022

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionAntioxidants may have positive impact on diabetic polyneuropathy (DPN), presumably due to alleviation of oxidative stress. We aimed to evaluate the efficacy and safety of combination of antioxidants: succinic acid, inosine, nicotinamide, and riboflavin (SINR) in the treatment of DPN.Research design and methodsIn a double-blind, placebo-controlled clinical trial, men and women aged 45–74 years with type 2 diabetes and symptomatic DPN, with initial Total Symptom Score (TSS) ˃5, were randomized into experimental (n=109) or placebo (n=107) group. Patients received study medication/placebo intravenously for 10 days, followed by oral administration for 75 days. Statistical significance was defined as a two-tailed p<0.05.ResultsIn SINR group, mean TSS change after 12 weeks was –2.65 (±1.46) vs –1.73 (±1.51) in the placebo group (p<0.0001; t-test). Reduction of symptoms in the SINR group was achieved regardless of hemoglobin A1c levels, but better results were observed in patients with initial TSS <7.5. The analysis of TSS subscores revealed statistically significant between-group differences by dynamics of the intensity of paresthesia and of numbness starting from day 11 (p=0.035 and p=0.001, respectively; mixed model); by day 57, statistically significant between-group differences were detected also by dynamics of burning intensity (p=0.005; mixed model). Study limitations are small effect size, moderate proportion of patients with severe DPN symptoms, subjective assessment of outcomes, exclusion of participants who received injectable glucose-lowering medications other than insulins, and patients with uncontrolled and type 1 diabetes.ConclusionsThe combination of SINR effectively alleviates DPN symptoms in patients with type 2 diabetes.Trial registration numberClinicalTrials.gov Registry (NCT04649203; Unique Protocol ID: CTF-III-DM-2019).

show abstract

Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders

Cited by 21 publications

References 10 publications

Pathogenetic and pharmacodynamic features of succinic acid derivative application for various diseases of the cardiovascular and nervous systems

Pathogenetic and pharmacodynamic features of succinic acid derivative application for various diseases of the cardiovascular and nervous systems

Selection of Neuroprotective Therapy in Patients with Chronic Cerebral Ischemia Taking Account of the Synergism of Drug Interactions

Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)

Contact Info

Product

Resources

About